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Abstract The peptide repertoire presented on human leu-
kocyteantigen(HLA)classImoleculesislargelydetermined
by the structure of the peptide binding groove. It is expected
that the molecules having similar grooves (i.e., belonging to
the same supertype) might present similar/overlapping
peptides. However, the extent of promiscuity among HLA
class I ligands remains controversial: while in many studies
T cell responses are detected against epitopes presented by
alternativemoleculesacross HLAclassIsupertypes andloci,
peptide elution studies report minute overlaps between the
peptide repertoires of even related HLA molecules. To get
more insight into the promiscuous peptide binding by HLA
molecules, we analyzed the HLA peptide binding data from
the large epitope repository, Immune Epitope Database
(IEDB), and further performed in silico analysis to estimate
the promiscuity at the population level. Both analyses
suggest that an unexpectedly large fraction of HLA ligands
(>50%) bind two or more HLA molecules, often across
supertype or even loci. These results suggest that different
HLA class I molecules can nevertheless present largely
overlapping peptide sets, and that “functional” HLA poly-
morphism on individual and population level is probably





peptides presented on human leukocyte antigen (HLA) class I
molecules. HLA class I genes are the most polymorphic loci
knowninthehumangenome:morethan2,000HLA-Aand-B
allelic variants have been reported (Bjorkman and Parham
1990; Parham and Ohta 1996; Marsh et al. 2010). Most
polymorphism is accumulated in the peptide binding groove
of these molecules, giving rise to specific binding motifs for
every HLA molecule, which allow for selective binding of a
set of peptides forming the so called ligand-binding
repertoire. HLA class I molecules may be grouped into
several supertypes based on their potential binding motif
similarity (Sette and Sidney 1999;L u n de ta l .2004;
Doytchinova et al. 2004; Kangueane et al. 2005; Reche and
Reinherz 2007; Hertz and Yanover 2007;S i d n e ye ta l .2008).
The specificity of HLA binding has been studied
extensively in the last 30 years. It has become clear early
on that some HLA molecules may significantly overlap in
peptide binding specificity (Sidney et al. 1995; Barber et al.
1995; Doolan et al. 1997; Bertoni et al. 1997; Threlkeld et
al. 1997), meaning that one peptide ligand has the ability to
bind to several HLA molecules. The majority of ligand
sharing was observed among molecules that have similar
binding motifs and therefore would be assigned to the same
HLA supertype, i.e., a form of promiscuity that may be
considered as “expected” (Brusic et al. 2002; Ueno et al.
2002; Burrows et al. 2003; Sidney et al. 2003; Takedatsu et
al. 2004; Frahm et al. 2005; Leslie et al. 2006). Few other
reports showed promiscuity across supertypes or even loci;
these findings were considered as “exceptions” (Sabbaj et
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DOI 10.1007/s00251-011-0552-6al. 2003; Masemola et al. 2004). Recently, however, two
systematic studies challenged this general view on promis-
cuity of HLA class I peptides and reported unexpected but
also conflicting results. Frahm et al. (2007) tested T cell
responses to 242 well-defined viral epitopes from HIV and
EBV in 100 subjects and found that 95% of these epitopes
elicited a T cell response in at least one individual not
expressing the original restricting HLA molecule. The
majority of potential alternative HLA molecules were not
matched to the same HLA supertype or even the same locus
as the original restricting HLA molecule. Shortly after this
study, Hillen et al. (2008) reported only minute overlaps
(3%) between the epitope repertoires of HLA molecules
belonging to the B44 supertype, based on several hundreds
of eluted peptides from nine members of the HLA-B44
supertype. This result was very surprising also because
Sidney et al. (2003) reported largely overlapping peptide-
binding repertoires for HLA molecules belonging to HLA-
B44 family, based on in vitro MHC binding experiments.
Of note, the experiments of Hillen et al. resulted in less than
30 peptides for some of the HLA molecules belonging to
this supertype (e.g., B*5001, B*4701 and B*4501; see
Hillen et al. 2008 and Table 3 of this article), suggesting
that the peptide elution approach might underestimate the
peptide binding repertoire of an HLA molecule.
Here we study the ligand sharing among HLA class I
molecules by carrying out a systematic study, in which we
analyze the data from Frahm et al. and Hillen et al. together
with a large amount of data available from the IEDB (www.
iedb.org; Vita et al. 2010) database. Although the experimen-
tal data in IEDB on MHC binding is extensive, it nevertheless
does not provide a reliable estimate of promiscuous binding
for every HLA molecule, because the number of HLA
molecules that can bind the same peptide depends largely on
the number of HLA molecules for which in vitro binding data
is available for the peptide in question. To avoid this problem,
we repeated the same analysis using state-of-the-art MHC
class I binding predictors (Nielsen et al. 2007; Lundegaard et
al. 2008;H o o fe ta l .2009) ,w h e r ew ee s t i m a t et h ee x t e n to f
promiscuous peptide binding by taking into account every
common HLA molecule in the population. In all cases, our
results suggest that more than 60% of HLA ligands show
promiscuous binding. Finally, we discuss consequences of the
extensive ligand sharing among HLA class I molecules in the
context of immunodominance and infectious diseases.
Results
HLA class I binding shows a high degree of promiscuity
To our knowledge, Frahm et al. (2007) were the first to
study HLA class I binding promiscuity systematically. In
short, a total of 242 known HIV-1 and EBV epitopes were
tested in a cohort of 100 (50 HIV-1 infected and 50 healthy)
subjects regardless of the individual's HLA type. This
cohort had a diverse HLA distribution, covering 46
(common) HLA-A, -B, and -C molecules. Almost all of
the tested epitopes, 95%, elicited a response in at least one
individual not expressing the original restricting HLA
molecule. Using two independent statistical approaches,
Frahm et al. predicted the alternative HLA molecules.
Surprisingly, the majority of potential alternative HLA
molecules were outside the original restricting molecule’s
supertype or even the locus (Frahm et al. 2007). Using the
pan-specific MHC class I binding predictor NetMHCpan
(Nielsen et al. 2007; Hoof et al. 2009), we confirmed 91%
of these alternative HLA restrictions among the most
significant associations and75% of all significant associa-
tions. This result suggests that the responses identified by
Frahm et al. are largely due to promiscuous presentation of
the same epitope via two or more HLA class I molecules,
instead of possible Tcell (CD4 and CD8) cross-reactivity to
different (embedded) epitopes presented by HLA class I
and II molecules. We observed that the predicted affinity for
the alternative HLA molecules in the data of Frahm et al. is
significantly lower than that for the original restricting HLA
(p=0.001, Mann–Whitney U test, for all associations). This
may explain why the responses elicited by alternative HLA
molecules could have been overseen so far, even though
MHC-peptide binding at lower affinity does not necessarily
result in lower T cell responses (Feltkamp et al. 1994;S e t t e
et al. 1994; Fortier et al. 2008).
To test the HLA class I binding promiscuity in an
independent data set, we analyzed HLA class I binding data
from the IEDB database (Vita et al. 2010) (details are given
in Materials and methods). This database covers approxi-
mately 99% of all publicly available information on peptide
epitopes mapped in infectious agents. Obviously, the
promiscuity of HLA binding depends on the number of
different HLA alleles for which peptide binding is tested.
To provide a realistic estimate of promiscuous HLA class I
binding, we selected IEDB peptide epitopes for which in
vitro binding assays were performed on at least six different
HLA class I molecules. We will refer to this data set as
"IEDB MHC binding data". With this criterion, a total of
3738 HLA class I binding peptides were retrieved, among
which 72% were promiscuous, i.e., reported to bind to at
least two HLA class I molecules (Table 1). Using a more
stringent criterion, e.g., when including only the peptides
which were tested on eight or ten HLA molecules, the
average promiscuity remained high (>65%, results not
shown). In line with the results of Frahm et al., 68% of
promiscuous HLA class I binding was observed across
serotypes, 47% across HLA supertypes, and 23% across
HLA loci (Table 1). Although being a much smaller data
692 Immunogenetics (2011) 63:691–701set, CTL response data from IEDB suggests similar levels of
promiscuity:Out of135non-redundant CTL epitopes,eachof
whichwastestedonatleastsixHLAalleles,82(60%)elicited
responses in the context of two or more HLA molecules.
Finally, to estimate the promiscuous peptide binding on
the population level, i.e., to estimate the chance of a peptide
being presented by two or more HLA molecules in a
population, we repeated a similar analysis using HLA
binding predictors and focused on the most frequent 20
HLA-A and 20 HLA-B alleles in four US subpopulations
with different ethnicity (European, Hispanic, African and
Asian ethnicities, data extracted from the National Marrow
Donor Program resource, http://bioinformatics.nmdp.org/;
Maiers et al. 2007). We predicted potential 9-mer binders to
these HLA molecules within common viral proteomes (n=
17, see Table S1) using NetMHCpan (Nielsen et al. 2007;
Hoof et al. 2009). This prediction method was demonstrated
to be the best one in a recent large benchmark performance
test (Zhang et al. 2009). The most frequent HLA molecules
(top 20 for A- and B-locus, respectively, listed in Table S4)
in all four ethnic groups have, on average, a fraction of
predicted promiscuous ligands around 60%, of which
almost half are predicted to be presented by multiple HLA
supertypes (Fig. 1). As expected, using a more stringent
threshold to define the peptide binding (e.g., a predicted
IC50 value of 50 nM instead of 500 nM) decreases the level
promiscuity to 35–40%, as the ligand repertoire for each
HLA molecule is severely reduced (results not shown).
These results were reproducible with another neural
network predictor, NetMHC3.2 (Lundegaard et al. 2008)
(see Materials and Methods for a discussion on the choice
of peptide–MHC binding predictors). Moreover, defining
top 1–2% ranking binders as predicted binders changed
only slightly the values reported in Table 1 and Fig. 1
(results not shown). In order to evaluate whether antigen
processing has an impact on ligand promiscuity, we then
added TAP and proteasomal cleavage predictions (Kesmir
et al. 2002; Nielsen et al. 2005; Tenzer et al. 2005) to our
MHC binding predictions. The level of promiscuity
remained very similar (data not shown), implying that
(predicted) antigen processing does not significantly influ-
ence the ligand sharing among HLA class I molecules.
Taken together, not only the data reported by Frahm et al.,
but also HLA binding data available in the large IEDB
repository and the analysis of HLA binding predictions on
population level strongly suggest that a high fraction of
HLA class I ligands (>60%) can bind to two or more HLA
molecules and, frequently, the observed promiscuity occurs
across different HLA class I supertypes.
Next we detailed our analysis at the supertype level to
pinpoint possible differences on ligand sharing among
different HLA class I supertypes. Analyzing IEDB MHC
binding data on per-supertype basis, we found that every
supertype have exceptionally many peptides that exhibit
promiscuous HLA binding (Table 2). The HLA-B44 super-
type, analyzed by Hillen et al. (2008) is somewhat an
“exception” among other supertypes: while 74% of the
B44-ligands reported in IEDB exhibit promiscuous binding,
across supertypes promiscuity is much lower at 17%
(Table 2). A similar result was obtained in in silico analysis
where we estimate the HLA peptide binding promiscuity on
the population level (see Table S2).
Comparison of different experimental approaches for HLA
peptide binding promiscuity
Hillen et al. (2008) undertook a different approach to study
HLAclassIbindingpromiscuitybydirectlycomparingligand
repertoires based on peptides eluted from HLA molecules. As
this is a very labor-intensive approach, they focused on a
single supertype: HLA-B44, of which nine members were
included in the elution study (listed in Table 3). Only a very
small fraction (25 out of 670, 3%) of the “natural” ligands
were found to bind two or more HLA molecules within the
Table 1 Summary of the promiscuity analysis of HLA class I ligands based on IEDB MHC binding data
Category Number of ligands Percentage of ligands (%)
All HLA class I ligands from IEDB (Tested on at least six HLA class I alleles) 3,738
Unique ligands 1,062 28
Promiscuous ligands
a 2,676 72
Promiscuous ligands across serotypes
b 2,526 68
Promiscuous ligands across supertypes
c 1,751 47
Promiscuous ligands across loci
d 864 23
aThe number of ligands that bind at least two different HLA alleles
bThe number of ligands that bind at least two different serotypes
cThe number of ligands that bind at least two different HLA supertypes
dThe number of ligands that bind at least two different HLA loci
Immunogenetics (2011) 63:691–701 693HLA-B44 supertype (Hillen et al. 2008). The binding
promiscuity of ligands from different allele varies between
18% to none, with an average of 10% (Table 3). This unique
data set allows us to compare the estimates of ligand sharing
(for B44 supertype only) using three different experimental
approaches: (i) T-cell binding (Frahm et al. 2007), (ii) eluted
peptides (Hillen et al. 2008) and (iii) HLA–peptide binding
measurements performed in vitro (IEDB data).
Frahm et al. tested the promiscuity of 20 CTL epitopes
restricted by four HLA-B44 supertype members (Table 3).
The far majority of those (17 epitopes) elicited a response
































Fig. 1 Distribution of predicted
HLA class I ligands of viral
origin. All predicted ligands of
the 20 most frequent HLA-A
and HLA-B molecules in US
subpopulations of a certain
ethnic background (European,
African, Asian and Hispanic)
were classified into three cate-
gories: unique ligands (exclu-
sively presented by one HLA
class I molecule), within-
supertype promiscuous ligands
(exclusively targeted by one
HLA supertype, but presented
by at least two class I HLA
molecules within this supertype)
and across-supertype promiscu-
ous ligands (targeted by HLA
molecules belonging to at least
two different HLA supertypes)
Table 2 Promiscuity of different HLA supertype ligands based on IEDB MHC binding data
HLA supertype N
a Promiscuous




HLA-A01 1,132 954 (84%) 438 (39%) 10
HLA-A02 868 797 (92%) 462 (53%) 14
HLA-A03 886 783 (88%) 289 (33%) 9
HLA-A24 887 815 (92%) 637 (72%) 4
HLA-B07 601 476 (79%) 375 (62%) 8
HLA-B08 273 200 (73%) 189 (69%) 3
HLA-B27 406 267 (66%) 197 (48%) 11
HLA-B44 624 460 (74%) 103 (17%) 6
HLA-B58 402 346 (86%) 258 (64%) 3
HLA-B62 701 637 (91%) 566 (81%) 3
aTotal number of unique ligands
bThe number of ligands reported to bind at least two different HLA molecules. Within parenthesis, the fraction with respect to the number of
ligands is given
cThe number (and fraction with respect to the number of ligands) of promiscuous ligands that are exclusively bind to the HLA molecules outside
of the supertype
694 Immunogenetics (2011) 63:691–701allele. Five of these CTL epitopes elicited T cell responses
in the context of another member of the HLA-B44 super-
type (25% within-supertype promiscuity, Table 3). This
result is similar to the one reported by Hillen et al., where out
of four CD8
+ T cell responses restricted by HLA-B44
molecules, only one epitope induced minor T cell responses
in individuals negative for the restricting allele, but positive
for a different HLA molecule within the B44 supertype
(Hillen et al. 2008). The remaining 12 promiscuous B44
restricted CTL epitopes identified by Frahm et al. elicited
responses in individuals that do not carry any HLA molecule
belonging to the HLA-B44 supertype (60% outside-
supertype promiscuity; Table 3).T cell response data
extracted from IEDB show a similar trend: out of 14 T cell
epitopes restricted by members of the B44 supertype and
tested on at least six HLA molecules, only two (14%) show
promiscuous binding within the supertype, while six epitopes
(43%) elicit T cell responses when presented by an HLA
molecule belonging to a different (non-B44) supertype.
Taken together, the results discussed above suggest that
the estimates of HLA binding promiscuity for B44 super-
type based on T cell responses (14–25% within supertype)
are higher than the estimates based on eluted peptides (3%
within supertype), and in vitro analysis of HLA binding
provides the highest estimate of HLA binding promiscuity
(see Table 2, 57% within supertype).
HLA-A and HLA-B molecules have similar levels of ligand
promiscuity
So far we did not distinguish between different HLA loci in
the promiscuity analysis. In the context of several infectious
diseases, immune responses to epitopes restricted by HLA-
B alleles were shown to be immunodominant (see, e.g.,
Kiepiela et al. 2004; Bihl et al. 2006). Moreover, particular
HLA-B alleles seem to be associated with either protection
or susceptibility to infectious diseases, best documented for
HIV-1 infection (e.g., Carrington and O’Brien 2003;
Kiepiela et al. 2004; Frahm et al. 2005; Pereyra et al.
2010). In order to see whether these features of HLA-B
restricted T cell responses may be due to the promiscuous
binding of HLA-B restricted epitopes, we compared their
binding promiscuity to HLA-A restricted epitopes. Since
Hillen et al. focused on HLA-B44 epitopes only, we used
the data from Frahm et al. to perform this analysis. Frahm
et al. tested 242 CTL epitopes tested, of which 148 and 181
epitopes were inferred to be presented by at least one HLA-
A and -B molecule, respectively. The number of epitopes
that were exclusively presented by a single HLA molecule
was slightly higher for HLA-A than for HLA-B (HLA-A:
37 out of 148, HLA-B: 28 out of 181, p=0.04, chi-square
test), suggesting that HLA-B restricted epitopes might
exhibit higher binding promiscuity. However, this differ-
ence between HLA-A and HLA-B epitopes was not to be
found in IEDB T cell assay data (HLA-A: 45 out of 117,
and HLA-B: eight out of 33, p=0.19, chi-square test), and
surprisingly, IEDB MHC binding data analysis suggested
that HLA-A ligands have a higher level of binding
promiscuity (p=0.02, Mann–Whitney U test; Fig. S1).
Due to these conflicting results on the experimental data,
we addressed the difference in the promiscuity of HLA-A
and HLA-B ligands also by using HLA binding predictions.
The fraction of peptides binding exclusively a single HLA
molecule remained similar in predicted HLA-A and HLA-B
Table 3 HLA-B44 alleles used by Hillen et al. (2008) and HLA-B44 epitopes tested by Frahm et al. (2007)




c Promiscuous Within B44 Promiscuous elsewhere
B*1801 121 (18%) 7 (5.7%) B18 4 0 3
B*37 60 (9%) 0 B37 1 0 1
B*4001 60 (9%) 8 (13.3%) B40 7 4 2
B*4101 38 (6%) 7 (18.4%) B44 8 1 6
B*4402 142 (21%) 14 (10%)
B*4501 29 (4%) 4 (13.8%)
B*4901 184(27%) 8 (4%)
B*5001 18 (3%) 3 (16.7%)
B*4701 27 (4%) 2 (7%)
Total 670 25
aThe number of peptides eluted from a specific allele. Within parenthesis, the fraction with respect to the total number of eluted peptides is given
bThe number of peptides eluted at least from two alleles within B44 supertype. Within parenthesis, the fraction with respect to the number of
eluted peptides from a specific allele is given
cThe number of CTL responses tested
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Whitney U test). We repeated this analysis using a different
set of criteria to define “binders” (i.e., using the top 1–2%
percentile, see Materials and methods) and by extending
our viral data set (Table S3), but in all cases we obtained
similar results.
Taken together, since the available experimental data
yield conflicting results and our in silico predictions
suggest no significant difference in promiscuous peptide
binding of HLA-A and HLA-B, we conclude that the
ligand binding promiscuity probably does not play a
major role in generating dominant HLA-B restricted
responses.
Functional consequences of HLA peptide binding
promiscuity in the context of HIV-1 infection
Our studies (see above) and others in the field provide solid
evidence showing that HLA class I ligands show a high
level of promiscuity. But why would HLA molecules have
promiscuous ligand binding? After all, it is believed that the
extensively polymorphic MHC has evolved due to a
selective advantage of being able to present epitopes on
rare MHC molecules in cases where the pathogens are
(fully) adapted to common MHC molecules (Borghans et
al. 2004). In search of a clue to explain functional aspects
of such a high degree of promiscuity, we studied the effect
of promiscuity on the disease outcome using HIV-1as a case
study. We speculated that the individuals carrying HLA
molecules with largely overlapping repertoires can be
considered “functionally homozygous” and may therefore
progress more rapidly to AIDS (Jeffery et al. 2000;
Carrington and O’Brien 2003). We calculated the fraction
of uniquely presented HIV-1 peptides for the frequent HLA
alleles (based on the predicted peptide repertoires of the top
20 HLA-A and HLA-B molecules) in the Caucasian
population. In line with the studies demonstrating that
HLA-B alleles show the strongest association with disease
outcome in HIV-1 infection (Kiepiela et al. 2004, 2007;
Leslie et al. 2010),we found a strong negative correlation
between the fraction of uniquely presented epitopes of
HLA-B molecules and median viral loads reported by
Fellay et al. (2009)( F i g .2a; r=−0.57, p=0.02, Spearman
correlation test) or the relative hazard (RH) reported by Gao
et al. (2001)( F i g .2b; r=−0.60, p=0.02, Spearman
correlation test).Remarkably, some protective alleles, like
B*2705 and B*5701, which have low RH and area-
ssociated with low viral load, have more unique ligand
repertoires than other alleles (82% and 56%, respectively,
see Table S5), implying that having less promiscuous
peptide presentation may contribute to viral control.
However, when we repeated this analysis with data from
the Durban cohort, infected mostly with HIV-1 clade C
(Leslie et al. 2010), the fraction of uniquely presented
epitopes no longer significantly correlated with the median
viral loads (results not shown).
Fig. 2 Correlation between the predicted fraction of unique ligands
for HLA-B molecules and mean set point viral load associated with
the same molecule or the relative hazard (RH).The fraction of uniquely
presented HIV-1 peptides for an allele was calculated by comparing
the predicted HIV-1 peptides for a particular allele with all the
predicted HIV-1 peptides for the most frequent HLA alleles (top 20
HLA-A and HLA-B as listed in Table S4) in the Caucasian population.
The predictions were performed with NetMHCpan (Hoof et al. 2009)
to obtain data for as many as possible alleles. The correlation between
the fraction of unique ligands and a mean set point viral load per HLA
molecule taken from Fellay et al. (2009)a n db RH taken from Gao et
al. (2001)a r es h o w n .F o r( b), whenever available we have used allele
specific RH; in other cases, we used the fraction of HIV-1 peptides
estimated for the most dominant HLA-B allele to correlate with the
relative hazard assigned to two digit HLA-B identifier (e.g., the
relative hazard associated with B*40 is correlated with the fraction of
unique HIV-1 peptides presented by HLA-B*4001). The Spearman
correlation coefficients and corresponding significance values are
reported in each figure. The data used to generate these graphs are
given in Table S5
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The genes of the human major histocompatibilitycomplex-
belong to the most polymorphic loci in the human
population. However, it is not yet clear whether this large
diversity at genotype level is reflected at the phenotype
level by distinct ligand repertoires. It has been known for a
long time that some HLA molecules have very similar
binding motifs, and thus these molecules can be grouped
into HLA supertypes (Sette and Sidney 1999; Lund et al.
2004; Doytchinova et al. 2004; Kangueane et al. 2005;
Reche and Reinherz 2007; Hertz and Yanover 2007; Sidney
et al. 2008). More recently, Frahm et al. demonstrated that
promiscuous HLA class I binding reaches beyond the
supertype: the far majority of HLA pairs that can elicit T cell
responses to the same peptide belong to different supertypes.
Following Frahm’s study on HIV-1 and EBVepitopes, it was
demonstrated that human papillomavirus (HPV) and Myco-
bacterium tuberculosis (TB) epitopes also show extensive
promiscuity of HLA class I binding when tested systemat-
ically (Nakagawa et al. 2007;A x e l s s o n - R o b e r t s o ne ta l .
2010) .T h e s ef i n d i n g sw e r ec h a l l e n g e db yH i l l e ne ta l .
(2008), who showed that even within a supertype, eluted
HLA ligands can show as little as 3%promiscuity.
We have taken another approach to estimate HLA
peptide binding promiscuity by using in vitro binding
measurements reported in the IEDB database (Vita et al.
2010). Moreover, in order to be able to estimate the
promiscuity of binding at the population level, i.e., by
testing peptide binding to all major HLA molecules in a
population, we performed in silico HLA–peptide binding
predictions. In both cases we found extensive promiscuity
in HLA class I ligand binding: 72% in the IEDB HLA
binding data and 60% in our predicted HLA ligands. In
addition, a high fraction of promiscuous ligands are found
to be ligands for at least two different HLA supertypes (see
Table 1, Fig. 1). As expected HLA supertype pairs with
similar binding motifs share more ligands (e.g., A2 and
B62 supertype ligands in IEDB overlap by 21%), than the
pairs with dissimilar motifs (e.g., only 4.4% B27 super-
type ligands in IEDB are also reported as binders for at
least one allele belonging to B44 supertype).Since our in
silico analysis covers different viruses and HLA molecules
common in different ethnic groups, we believe that our
results provide solid evidence for a high level of
promiscuity being an intrinsic characteristic of HLA
binding, regardless of the source of the ligand and the
HLA molecule.
Why then was the fraction of shared ligands in the study
by Hillen et al. as low as 3%? Unfortunately, our efforts did
not produce a concrete answer to this question. Remarkably,
the number of peptides eluted per allele by Hillen et al. was
low (summarized in Table 2), considering that around
100,000 MHC molecules are expected to be on the cell
surface at a time (Yewdell et al. 2003). This might be
(among others) due to degradation of presented peptides
under the rather harsh conditions necessary for the elution.
If the elution studies underestimate the peptide repertoires,
then the overlaps between the peptide repertoires of
different MHC molecules might be underestimated as well.
I n d e e d ,w h e nw eu s eas t r i n g e n tthreshold to define binders
in our in silico analysis, the predicted peptide repertoire of
individual HLA molecules is reduced and as a consequence
the average promiscuity decreases (data not shown).
By sampling eluted peptides, Hillen et al. may have
biased their data to high affinity MHC binders. When we
predicted the MHC binding affinity for the eluted peptides
from the B44 supertype, we found that the median
predicted binding affinity was lower than 50nM, which is
generally used as a cutoff to discriminate high binders (e.g.,
for B*1801 the median affinity is 9 nM, and for B*4001 the
median affinity is 27 nM). Following this, promiscuity of
high affinity binders may be lower than of MHC ligands in
general. However, this explanation is not in line with the
earlier studies, which suggest that high affinity binders also
tend to be the most promiscuous binders (Sidney et al.
1996, 2001; Sette et al. 2003). Similarly, we found a
significant (but weak) negative correlation between ligand
binding affinity and promiscuity (r=−0.27, p<0.0001,
Spearman correlation test), suggesting that the promiscuous
binding among high affinity binders should be even higher
than on average. Taken together, earlier studies and our
present study suggest that the lower promiscuity observed
by Hillen et al. might be due to other mechanisms than
MHC binding per se.
The functional consequences of the extensive ligand
sharing among HLA class I molecules remain to be
discovered. In order to see whether promiscuous ligand
presentation might be the underlying reason of immunodo-
minance by HLA-B restricted Tcell responses, we compared
promiscuity between different HLA-A and HLA-B ligands.
However, our numerous attempts did not result in a
consistent picture (see section on HLA-A and -B), suggest-
ing that there is not a direct association between (non-)
promiscuous ligand presentation and dominant T cell
responses. On the other hand, we have found a relationship
between the fraction of uniquely presented peptides and HIV-
1 disease progression, where HLA molecules associated with
slow disease progression are also the ones that have the
lowest degree of promiscuity (see Fig. 2). We believe that
carrying HLA molecules with unique peptide repertoires
increase the heterozygous advantage, based on the principle
that individuals heterozygous at HLA loci are able to
present a greater diversity of antigenic peptides than are
homozygotes (Dean et al. 2002). The heterozygous advan-
tage was suggested to generate a more effective immune
Immunogenetics (2011) 63:691–701 697response and therefore resulted in better control of HIV-1
infection (Carrington et al. 1999). In addition, the individ-
uals with HLA molecules having unique binding motifs
have lower chances of transmission of a pre-adapted virus.
More data on HLA associations and disease outcome will
help to resolve the functional aspects of the high level of
promiscuity among HLA class I epitopes and especially
how it affects an individual’sf i t n e s s .
Materials and methods
Experimental MHC binding and T cell response data
The experimental data used in our analysis was extracted
from the Immune Epitope Database and Analysis Resource
(IEDB; www.immuneepitope.org; downloads were made in
March 2010). The first data set included all peptides for
which the HLA class I binding affinity was determined by
in vitro MHC binding assays; the second data set consisted
of peptides with measured T cell responses. We considered
only peptidesthatweretested on at least six HLA class I
molecules and with an IC50 value lower than 500 nM for at
least one of these molecules (i.e., the peptide has to be a
binder for at least one HLA molecule). In addition, to make
sure that all HLA–peptide associations were well defined,
only the data with four-digit HLA class I identifierswere
included. These selection criteria resulted in a set of 3,738
non-redundant peptides obtained from the MHC binding
assay database of IEDB and is herereferred to as “IEDB
MHC binding data”. The Tcell response data, filtered using
the same criteria, resulted in a much smaller data set.
Therefore, we relaxed the requirements on four digit HLA
identifiers by including T cell response data for which only
one- or two-digit HLA identifiers were available. In total,
filtering of the IEDB T cell assay data resulted in 135 non-
redundant T cell epitopes.
Quantifying HLA binding promiscuity
We divided the ligands of a particular HLA class I
molecule into two groups: (i) unique ligands, which are
exclusively presented by this HLA class I molecule; (ii)
promiscuous ligands, which are capable to bind to at least
one other HLA class I molecule. We define the fraction of
the unique ligands as, Fu ¼ Nu
Nall, where Nu is the number of
unique ligands and Nall is the total number of ligands. In
order to estimate this fraction as reliably as possible, we
calculated it only for the HLA molecules for which more
than ten peptides were experimentally tested on alternative
HLA molecules. Changing this arbitrary threshold of 10 (to
20 or 30) did not change the results reported in the text
(data not shown).
Promiscuity at supertype level
Throughout our analysis, we followed allele-supertype
associations defined by Sidney et al. (2008) except in a
single case: HLA-B*4901 is not classified into any super-
type by Sidney et al., and therefore, we assigned it to the
B44 supertype, as was done by Hillen et al. (2008).
In silico analysis
HLA allele selection
HLA allele frequencies were obtained from the National
Marrow Donor Program (NMDP) website (bioinformatics.
nmdp.org) for four predominant US census categories of
race and ethnicity: African Americans, Asians, European
Americans and Hispanics (Mori et al. 1997; Maiers et al.
2007). We included the 20 most frequent HLA-A and 20
most frequent HLA-B alleles for each ethnic group into our
in silico analysis (Table S4A, S4B). The peptide–MHC
binding predictions for majority of these molecules are of
high quality (Hoof et al. 2009).
HLA class I ligand prediction
To have an as large as possible population coverage, we
used NetMHCpan (Hoof et al. 2009) to predict peptide–
HLA binding affinity. NetMHCpan assigns to each peptide–
HLA pair a predicted IC50 value, indicative of the predicted
binding affinity. An IC50 threshold of 500 nM was used to
discriminate HLA binding ligands from nonbinding pep-
tide. NetMHCpan is not an allele specific method: it has
been trained on peptide binding data for many different
MHC molecules (also from non-human species), and its
prediction relies on intra- and extrapolation from charac-
terized to uncharacterized HLA alleles. Thus, NetMHCpan
may overestimate the promiscuity of HLA class I peptides.
In order to check this issue, we compared NetMHCpan with
an allele-specific predictor NetMHC3.2 (Buus et al. 2003;
Nielsen et al. 2008;L u n d e g a a r de ta l .2008). A total of 42
HLA molecules (21 HLA-A and 21 HLA-B) have
NetMHC3.2 predictions available. For each HLA molecule,
we calculated the fraction of unique ligands to estimate the
promiscuity of its ligands, by using the prediction results
obtained from NetMHC3.2 and NetMHCpan. Predicted
promiscuity of HLA class I binding by both predictors is
highly correlated (p<0.001, r=0.86, Pearson correlation
test). Moreover, both predictors estimate the fraction of
promiscuous ligands restricted by these 42 HLA alleles to
be around 58–60% (data not shown and Fig. 1). These
results suggest that using NetMHCpan, which has a broader
population coverage than NetMHC, would not result in an
overestimation of promiscuity of HLA ligands.
698 Immunogenetics (2011) 63:691–701Using a fixed threshold of 500 nM IC50 to define
predicted binders may result in differences in predicted
repertoire sizes between HLA molecules, which in turn may
introduce a bias into the promiscuity analysis (MacNamara
et al. 2009). To avoid this, we repeated the analysis by
defining the top 1% of the peptides as candidate binders for
each HLA molecule, thereby ensuring the same ligand
repertoire size for each HLA molecule. With this alternative
scaled threshold approach, all in silico results reported in
this paper remain unchanged. For example, for the
European subpopulation the predicted promiscuity of
HLA class I binders is 57% with the fixed threshold of
500 nM and 54% with the scaled threshold.
Predicting antigen processing
The Stabilized Matrix Method (SMM) was applied to
predict TAP transport efficiency and proteasomal cleavage,
which are the two main steps of antigen processing (Tenzer
et al. 2005). Applying an alternative predictor of antigen
processing, NetChop (Kesmir et al. 2002; Nielsen et al.
2005), did not affect our results.
Viral data
The proteomes of 17 common human viruses were down-
loaded from the European Bioinformatics Institute website
(www.ebi.ac.uk; downloads were made in Oct 2006, listed
in Table S1) as the source of potential HLA ligands. We
used the HLA, TAP and proteasome predictors to screen all
possible unique virus-derived 9-mer peptides for potential
HLA ligands. This data set is later extended with the
viruses given in Table S3 to test the dependence of our
results on the initial set of viral proteomes.
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